| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Oxytocin free acid TFA targets oxytocin receptors (OTR), G protein-coupled receptors (GPCRs) primarily expressed in the uterus, mammary gland, and brain. The C-terminal amide of native oxytocin is essential for high-affinity binding and full agonist activity. Replacement with a free acid drastically reduces receptor binding affinity and functional activation. The analog also shows reduced binding to vasopressin receptors (V1aR, V1bR, V2R) but may retain residual affinity at these related GPCRs. The reduced activity makes this analog useful for distinguishing receptor-specific effects from non-specific peptide-receptor interactions.
|
|---|---|
| ln Vitro |
The in vitro activity of oxytocin free acid TFA is substantially reduced compared to native oxytocin. Whereas native oxytocin induces potent contractile responses in uterine smooth muscle and myoepithelial cells with EC50 values in the low nM range, the free acid analog exhibits significantly weaker activity (typically <0.1% of native). The loss of the C-terminal amide disrupts optimal orientation of the C-terminal tripeptide (Pro-Leu-Gly) within the receptor binding pocket, preventing full receptor activation. Nonetheless, the analog may still bind to the receptor as a partial agonist or weak antagonist in certain assay systems.
|
| ln Vivo |
No specific in vivo data for oxytocin free acid TFA is provided in the search results. Based on its markedly reduced in vitro activity, the analog is expected to exhibit minimal uterotonic, milk-ejecting, or behavioral effects in animal models compared to native oxytocin. It may act as a weak oxytocin receptor antagonist in vivo at sufficiently high doses, but this has not been systematically characterized. The compound is primarily used as a research tool for receptor occupancy studies rather than as an in vivo pharmacological agent.
|
| Enzyme Assay |
Cell-free receptor binding assays can be performed using membrane preparations from CHO cells stably expressing human oxytocin receptors. Membranes (10-20 microg/well) are incubated with 0.1 nM [3H]-oxytocin as radioligand and varying concentrations of unlabeled oxytocin free acid TFA (0.1 nM-100 microM) in binding buffer (50 mM Tris-HCl pH 7.4, 5 mM MgCl2, 0.1% BSA) for 60 minutes at 25degC. Non-specific binding is determined with 1 microM unlabeled oxytocin. Bound radioligand is separated by vacuum filtration through GF/B filters presoaked in 0.3% PEI, followed by three washes with ice-cold buffer. Filters are dried and counted. Ki is calculated from IC50 using the Cheng-Prusoff equation. The analog typically displays Ki values in the microM range, indicating low micromolar affinity.
|
| Cell Assay |
Functional assays in oxytocin receptor-expressing CHO cells are used to assess receptor activation. Cells seeded in 96-well plates are loaded with 2 microM Fluo-4 AM (60 min, 37degC). After washing, serial dilutions of oxytocin free acid TFA (0.01 nM-100 microM) are added to the cells. Intracellular calcium responses are monitored in real-time using a fluorescence plate reader (ex/em 494/516 nm). Alternatively, aequorin-based luminescence assays using mitochondria-targeted aequorin can be employed for high-throughput screening. EC50 values are determined from dose-response curves. The free acid analog typically shows an EC50 >10 microM compared to native oxytocin EC50 of ∼10 nM.
|
| ADME/Pharmacokinetics |
The lyophilized powder has a molecular weight of 1122.20 g/mol with formula C45H66F3N11O15S2. The compound should be stored at -80degC for long-term storage (up to 2 years) or at -20degC for up to 1 year, in sealed containers away from moisture. For solution storage, the compound should be kept at -80degC (6 months) or -20degC (1 month) in sealed, moisture-protected vials. The TFA salt form enhances water solubility relative to the free base. Working solutions can be prepared in DMSO or sterile water. The compound appears as a white to light yellow solid.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human therapeutic applications. No specific toxicity data is available for the free acid analog. The TFA counterion may be cytotoxic if present at high concentrations (>0.1%) but is generally safe at standard research dilutions. Standard laboratory safety practices should be followed, including the use of personal protective equipment (PPE) such as gloves, lab coats, and safety glasses. The compound is not intended for clinical use. Avoid inhalation of powder and contact with skin or eyes.
|
| References |
[1]. Ferrier BM, et al. 9-Deamidooxytocin, an analog of the hormone containing a glycine residue in place of the glycinamide residue. J Med Chem. 1966;9(1):55-57.
[2]. Carter CS, Kenkel WM, MacLean EL, et al. Is Oxytocin "Nature's Medicine"?. Pharmacol Rev. 2020;72(4):829-861. |
| Additional Infomation |
Oxytocin is a pleiotropic peptide hormone with broad implications for general health, adaptation, development, reproduction, and social behavior. The C-terminal amide (glycinamide) is essential for high-affinity receptor binding and full agonist activity; its removal dramatically reduces bioactivity. Oxytocin free acid is sometimes referred to as 9-deamidooxytocin. This analog is a negative control in oxytocin receptor functional studies. The free base form (without TFA) is CAS 4248-64-0. The compound is not an FDA-approved drug and is intended for research purposes only. Supplier information must not be included.
|
| Molecular Formula |
C45H66F3N11O15S2
|
|---|---|
| Related CAS # |
Oxytocin free acid;4248-64-0
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
